Company description

Codexis is a leading protein engineering company applying innovative technologies to Unlock the Power of ProteinsTM. We work collaboratively with our clients to advance protein optimization and production, enabling breakthrough developments in pharmaceuticals and fine chemicals, biotherapeutics, food & beverage, agriculture and other industries.


Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Primary business activity Manufacturer; Service
Affiliated categories: Biopharmaceuticals (general category) |Enzymes |Protein Chemistry More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 42G43 See our Exhibitor Profile   See full Exhibitor List

News about Codexis, Inc

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Codexis and Takeda collaborate to advance novel gene therapies

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more

8 Aug 2017

Codexis Obtains Court Order Awarding Summary Judgment of Patent Infringement against EnzymeWorks

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, on Tuesday secured a federal court order awarding it summary judgment on 10 claims of patent infringement it brought in a lawsuit against Suzhou, China-based EnzymeWorks, Inc. and its San Diego-based affiliate, also called EnzymeWorks, Inc. The court’s order establishes EnzymeWorks’ uncontested infringement of 10 of Codexis’ patents and eliminate...

Read more

31 Mar 2017

Codexis Signs Second Multi-Year Agreement in Food Industry with Tate & Lyle

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the signing of a multi-year development agreement with Tate & Lyle, a global provider of food ingredients and solutions.  This is the second multi-year agreement signed in recent months between Codexis and Tate & Lyle and highlights Codexis’ continued growth applying its CodeEvolver® protein engineering platform technology in the food industry.  T...

Read more

6 Jan 2017

Codexis to Offer High-Performance Enzymes for Diagnostics Markets

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it will offer high-performance enzymes for customers using next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) for in vitro molecular diagnostic applications.  Codexis’ first proprietary enzyme for this market will target improved library preparation for NGS users, and is expected to be available in beta-test format by the second quarte...

Read more
Codexis, Inc

Contact information




View all contact information